CCR4 expression in rare subtypes of cutaneous T-cell lymphomas (CTCL) a non-interventional restrospective multicenter study

CCR4 expression in rare subtypes of cutaneous T-cell lymphomas (CTCL) a non-interventional restrospective multicenter study - CCR4-CTCL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034511

Enrollment

Registered

2024-06-19

Start date

2024-07-17

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ORPHA:178528

Interventions

Group 1: Adult patients with rare CTCL subtypes for whom sufficient and diagnostic FFPE tumor material is available. The following data/results will be analysed

demographic data CCR4-Expression in skin lesions Time to next treatment Tumor-associated and overall Survival Group 2: Patients with mycosis fungoides and Sézary syndrome and patients with inflammator

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Main group: Inclusion criteria: Adult patients with rare CTCL subtypes for whom adequate and diagnostic FFPE tumor material is available. Control group: - Patients with mycosis fungoides and Sézary syndrome - Patients with inflammatory skin diseases

Exclusion criteria

Exclusion criteria: Main group: -Patients with mycosis fungoides (MF) and Sézary syndrome (SS) -Patients with non-validated diagnosis

Design outcomes

Primary

Measure	Time frame
- Primary endpoint: overall survival of patients with different CCR4 expression levels	—

Secondary

Measure	Time frame
-Secondary endpoint: time to next treatment in patients with different CCR4 expression levels	—

Countries

Germany

Contacts

Public ContactRose Moritz

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany

rose.moritz@charite.de+49 30 450 518041

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026